These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6085198)

  • 1. New poliovirus vaccines: a molecular approach.
    Almond JW; Stanway G; Cann AJ; Westrop GD; Evans DM; Ferguson M; Minor PD; Spitz M; Schild GC
    Vaccine; 1984 Sep; 2(3):177-84. PubMed ID: 6085198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines.
    McBean AM; Thoms ML; Albrecht P; Cuthie JC; Bernier R
    Am J Epidemiol; 1988 Sep; 128(3):615-28. PubMed ID: 2843039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infectious cDNA, cell receptors and transgenic mice in the study of Sabin's poliovirus vaccines.
    Racaniello VR
    Biologicals; 1993 Dec; 21(4):365-9. PubMed ID: 8024752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys.
    Murray MG; Kuhn RJ; Arita M; Kawamura N; Nomoto A; Wimmer E
    Proc Natl Acad Sci U S A; 1988 May; 85(9):3203-7. PubMed ID: 2834736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
    Minor PD
    Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative characteristics of live vaccine against poliomyelitis prepared in the Institute of Poliomyelitis Research of the AMN SSSR, and Sabin's vaccine from attenuated strains of the poliomyelitis virus].
    CHUMAKOV MP; GAGARINA AV; LASHKEVICH VA; DZAGUROZ SG; RAL'F NM; FLEER GP; VOROSHILOVA MK; ROBINZON Ia
    Vopr Virusol; 1959; 4():533-7. PubMed ID: 13810206
    [No Abstract]   [Full Text] [Related]  

  • 9. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular biology of poliovaccines.
    Minor PD
    J Gen Virol; 1992 Dec; 73 ( Pt 12)():3065-77. PubMed ID: 1335021
    [No Abstract]   [Full Text] [Related]  

  • 11. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
    Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
    Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: "Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines".
    Arya SC
    Am J Epidemiol; 1990 Jan; 131(1):202-3. PubMed ID: 2152841
    [No Abstract]   [Full Text] [Related]  

  • 13. sIPV process development for costs reduction.
    Thomassen YE; Bakker WA
    Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [STUDY ON POLIOVIRUS INFECTIONS IN CHILDREN OF COLLECTIVES VACCINATED WITH SABIN'S LIVE VACCINE].
    CHAPURSKAIA NO; CHERNOVA Ia; KIRICHINSKAIA IO; BORODAI VM
    Pediatr Akus Ginekol; 1964; 4():30. PubMed ID: 14294012
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.
    Swartz TA; Handsher R; Manor Y; Stoeckel P; Barkay A; Mendelson E; Leventhal A
    Vaccine; 1998 Dec; 16(20):2090-5. PubMed ID: 9796069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines.
    Zhaori G; Sun M; Faden HS; Ogra PL
    J Infect Dis; 1989 Jun; 159(6):1018-24. PubMed ID: 2470831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
    Kersten G; Hazendonk T; Beuvery C
    Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
    J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.
    Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
    J Gen Virol; 1990 Nov; 71 ( Pt 11)():2543-51. PubMed ID: 1701474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.